WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



XNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C12N 15/12, 1/21, 5/16, C12Q 1/68, C07K 14/47, 14/705, 16/18, A61K 48/00

A3

(11) International Publication Number:

WO 98/28332

(43) International Publication Date:

2 July 1998 (02.07.98)

(21) International Application Number:

PCT/US97/23761

(22) International Filing Date:

22 December 1997 (22.12.97)

(30) Priority Data:

08/772,440

20 December 1996 (20.12.96) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application

US

08/772,440 (CIP)

Filed on

20 December 1996 (20.12.96)

(71) Applicant (for all designated States except US): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ARIIZUMI, Kiyoshi [JP/US]; 9607 Walnut Street #11106, Dallas, TX 75243 (US). TAKASHIMA, Akira [JP/US]; 2209 Pistachio Drive, Irving, TX 75063 (US).

(74) Agent: BOWLES, Teresa, J.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:

29 October 1998 (29.10.98)

(54) Title: UNIQUE DENDRITIC CELL-ASSOCIATED C-TYPE LECTINS, DECTIN-1 AND DECTIN-2; COMPOSITIONS AND **USES THEREOF**

(57) Abstract

Novel genes expressed selectively by long-term dendritic cell (DC) lines (XS series) from murine epidermis which retain important features of resident epidermal Langerhans cells (LC) are provided. These genes encode distinct type II membrane-integrated polypeptides, each consisting of a cytoplasmic domain, a transmembrane domain, an extracellular connecting domain, and a C-terminal extracellular domain that exhibits significant homology to the carbohydrate recognition domains (CRD) of C-type lectins. Expression of both genes is highly restricted to cells of DC lineage (including epidermal LC). Thus, these genes encode new, DC-specific members of the C-type lectin family, now termed "DC-associated C-type lectin-1 and -2" (dectin-1 and dectin-2). Two isoforms of the dectin-1 molecule and five isoforms of the dectin-2 molecule have also been identified. The invention further provides His-tagged fusion proteins comprising 6x histidine and the extracellular domain of dectin-1 or dectin-2. Also provided are antibodies raised to synthetic peptides designed from the dectin-1 sequence or to the His-tagged fusion proteins described.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
АT	Austria	FR	France	LU	Luxembourg	SN -	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Мопасо	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israei	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy _.	, MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	· NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		•
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Intern. ial Application No PCT/US 97/23761

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/12 C12N1/21 C12Q1/68 C07K14/47 C12N5/16 CO7K14/705 A61K48/00 . CO7K16/18 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) C12N C12Q C07K A61K IPC 6 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category ' Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Ε WO 98 02456 A (INCYTE PHARMA INC ; AU YOUNG 1,2,5,6, JANICE (US); COCKS BENJAMIN GRAEME (US) 22 38,39, January 1998 42, 45-60, 90-96, 98,99, 103 see the whole document WO 96 23882 A (UNIV ROCKEFELLER; STEINMAN Χ 1,2,5,6, RALPH M (US); NUSSENZWEIG MICHEL C (US)) 8 38,39, August 1996 42, 45-60, 90-96, 98.99. 103 see the whole document Χ Further documents are listed in the continuation of box C. Patent family members are listed in annex. ΙX Special categories of cited documents : "T" later document published after the international filing date or priority date and not in conflict with the application but "A" document defining the general state of the art which is not cited to understand the principle or theory underlying the considered to be of particular relevance invention *E* earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the "O" document referring to an oral disclosure, use, exhibition or document is combined with one or more other such documents, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report **U** 8. 09. 98 21 April 1998 Name and mailing address of the ISA **Authorized officer** European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Hillenbrand, G Fax: (+31-70) 340-3016

Interr nal Application No
PCT/US 97/23761

		PCT/US 97/23761				
C.(Continu Category °	Intinuation) DOCUMENTS CONSIDERED TO BE RELEVANT					
Jalegory	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.				
(SUZUKI N ET AL: "MOLECULAR CLONING AND EXPRESSION OF CDNA ENCODING HUMAN MACROPHAGE C-TYPE LECTIN" JOURNAL OF IMMUNOLOGY, vol. 156, no. 1, 1 January 1996, pages 128-135, XP002046614	1,2,5,6, 38,39, 42, 45-60, 90-96, 98,99, 103				
	see the whole document					
(*ARIIZUMI K ET AL: "Cloning of novel C-type *lectins* that are expressed selectively by dendritic cells" JOURNAL OF INVESTIGATIVE DERMATOLOGY, 106 (4). 1996. 814., XP002062819	1,2,5,6, 38,39, 42, 45-60, 90-96, 98,99, 103				
	see the whole document					
		·				
	·					
	1					

International application No.

PCT/US 97/23761

BOX 1 Observations where certain claims were round unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Claims Nos.: X because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: See attached sheet
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
See attached sheet
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. X No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Claims 1 - 60, 90 - 103
•
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search lees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-60, 90-103

This group of claims is directed to a DNA segment encoding a dectin-1 or dectin-2 polypeptide, a recombinant host cell comprising such a DNA segement, a composition comprising a purified dectin-1 or dectin-2 polypeptide, a fusion protein comprising such polypeptides, and an antibody that is reactive with these dectin-1 or dectin-2 polypeptides.

2. Claims: 61-68

This group of claims is directed to a nucleic acid segment having no defined functional properties.

3. Claims: 69-71

This group of claims is directed to a dectin-like gene.

4. Claims: 72-89

This group of claims is directed to a method of identifying a human nucleic acid segment that comprises an isolated coding region that encodes a human dectin-like polypeptide.

5. Claims: 104-108

This group of claims is directed to a method for inhibiting the interaction of DC with a T cell.

6. Claims: 109-112

This group of claims is directed to a method of treating inflammation.

7. Claims: 113-122

This group of claims is directed to a method for identifying an effector of DC interaction with T cells.

8. Claim: 123

This group is directed to a method for identifying an inhibitory agent.

9. Claim: 127

This group is directed to a method for purifying T cells.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

10. Claim: 128

This group is directed to a method for identifying a stimulatory agent.

11. Claim: 132

This group is directed to a method of engineering a DC that does not express dectin-1 or dectin-2.

12. Claims: 133-136

This group of claims is directed to a method for targeting gene expression in a cell.

13. Claims: 137-140, 148-151

This group of claims is directed to a DNA segment comprising a dectin promoter element and a pharmaceutical composition comprising such a promoter element.

14. Claim: 141

This group is directed to a method of suppressing the expression of a dectin-1 or dectin-2 gene in a cell.

15. Claim: 143

This group is directed to a method of producing a transgenic animal.

16. Claim: 146

This group is directed to a method for identifying a ligand of dectin-1 or dectin-2.

International Application No. PCT/ US 97/23761

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This international search report has not been established in respect of certain claims for the following reasons:

Claims Nos.:

13, 124-126, 129-131, 142, 144-145, 147

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extend that no meaningful international search can be carried out, specifically:

The content of said claims is so obscure that no meaningful search can be carried out.

Information on patent family members

Intern nal Application No PCT/US 97/23761

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9802456	22-01-1998	AU 3665097 A	09-02-1998
WO 9623882	08-08-1996	AU 4970296 A CA 2211993 A EP 0808366 A	21-08-1996 08-08-1996 26-11-1997